TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
EHE Global Research Convened in Milan, Italy
In September 2023, EHE Director of Research Denise Robinson met over three days in Milan, Italy, with patient advocates and researchers to discuss EHE research funded by this community. Exciting progress is happening in this multi-national collaborative research under the leadership of Dr. Silvia Stacchiotti and Dr. Nadia Zaffaroni (Istituto Nazionale Tumori IRCCS, Milan), and […]
Funded Research Project Update: Use of pre-clinical EHE models to identify druggable pathways to treat EHE
Investigator: John Lamar, PhD, Albany Medical College Dr. Lamar was awarded a 3-year grant by The EHE Foundation in 2022, that aims to identify FDA-approved drugs that inhibit EHE cell growth, and then test them in pre-clinical mouse models for the treatment of EHE. What does this mean for patients? This could mean a shorter […]
Funded Research Project Update: Repurposing an FDA-approved Drug for EHE Treatment
Investigator: Ajaybabu Pobbati, PhD, Cleveland Clinic – Lerner Research Institute In 2022, The EHE Foundation funded a grant to Dr. Pobbati for research that looks at a library of current FDA-approved drugs that act as TAZ-CAMTA1 (TC) or TEAD inhibitors, for use in EHE. What does this mean for patients? This could mean a shorter […]
Championing Our Cause: How Patients Support Fundraising
Join us for EHE Community Connections as we discuss “Championing Our Cause: How Patients Support Fundraising.” Collaborate with other patients and caregivers to explore the most creative and effective fundraising ideas. Together, let’s talk about how to better engage our own community of donors, create awareness and raise money for this one-in-a-million cancer! This workshop […]
The Pledge: Edition 33, Q2 – April-June, 2023
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more! Click here to view the most recent edition of our online EHE newsletter, The Pledge.
July is Sarcoma Awareness Month – Support Our Mission With a Monthly Donation
As we spread sarcoma awareness this month, we ask you to consider a monthly donation. A recurring donation creates a BIG impact in a rare sarcoma, like EHE. We’ve set a goal of 10 new monthly donors! Will you join our Circle of Friends? It’s very affordable and connects you to our small, but mighty […]
Farzaad D.
Farzaad’s Story: Facing EHE with Faith, Strength, and Positivity For Farzaad, the first signs that something was wrong were easy to notice, but impossible to explain. Around May 2025, he began experiencing swelling in his face that did not feel normal. He also found himself becoming short of breath more easily. Over time, other changes […]
Advocacy in Action: ESMO Sarcoma and Rare Cancers Congress & EHE Research Meeting
In March, EHE Foundation was represented at two important meetings in Europe focused on sarcoma, rare cancers, and EHE research. These gatherings were invaluable opportunities to connect with clinicians, researchers, and fellow advocates working to improve care, deepen understanding, and advance progress for people affected by EHE. Executive Director Denise Robinson attended on behalf of […]
Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials
Following the publication of results from a phase 2 study of eribulin in two vascular sarcomas, angiosarcoma and EHE, Dr. Tom Chen of National Taiwan University College of Medicine shared commentary in Clinical Cancer Research. He praised the investigators for their collaborative study while also pointing to important considerations for future research. Although angiosarcoma and […]